A new report from IMS Health showed that Otsuka Pharmaceutical's antipsychotic drug Abilify, or aripiprazole, continues to be the best-selling drug in the U.S., with almost $6.9 billion in sales from April 2013 to March 2014. AstraZeneca's proton pump inhibitor Nexium, or esomeprazole, ranked second, with almost $6.3 billion in sales, followed by AbbVie's arthritis drug Humira, or adalimumab, with sales of $5.9 billion. The two most-prescribed drugs during the period were AbbVie's hypothyroid drug Synthroid and AstraZeneca's cholesterol-lowering drug Crestor.

Related Summaries